FDA recalls Philips CT scanner
The Food and Drug Administration has recalled 15 Philips Medical Systems Tomoscan SR4000 CT scanners because of a defect that shows up when an image is reversed in the system’s databank, according to an FDA enforcement report. The defect in the
The Food and Drug Administration has recalled 15 Philips Medical Systems Tomoscan SR4000 CT scanners because of a defect that shows up when an image is reversed in the systems databank, according to an FDA enforcement report. The defect in the system causes a patients image to be reversed left to right when a clinician retrieves it.
The problem was found during a routine FDA inspection several months ago, a Philips official said. He said the company hasnt received any complaints from customers.
There has to be a very specific set of circumstances for (the defect) to happen, the Philips official said. We have identified it as possible, and we are taking steps to correct the information.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 2
July 25th 2025In the second of a multi-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, share their perspectives on remote MRI safety protocols for ensuring screening accuracy and adherence to conditional implant guidelines as well as a rapid and effective response to adverse events.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 2
July 23rd 2025In the second part of a multi-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, discuss key sequences for abbreviated breast MRI and how it stacks up to other breast cancer screening modalities.
Chest CT for Post-COVID-19 Abnormalities: Nine Takeaways from a Multi-Society Consensus Statement
July 22nd 2025Developed by 21 thoracic radiologists, the new international consensus statement addresses appropriate indications, scan acquisition and keys to reporting for the use of chest CT imaging in evaluating for residual lung abnormalities from COVID-19.
